Cancer name Anaplastic Thyroid Carcinoma
Cancer Type THCA
Immunotherapy type Oncolytic viruses
Treatment dl922-947
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature IL-8
Official Symbol CXCL8
Mode of action PROT_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Interestingly, both cell lines produced high levels of IL-8 and CCL2, which were reduced upon treatment with dl922-947 but not AdGFP.The latter results were confirmed by Real-Time PCR analysis of mRNA levels. In addition, we observed the same pattern of IL-8 and CCL2 secretion when the concentrations of these chemokines were normalized on the total cellular protein content to account for dl922-947-induced cell death.
PMID 26625205
Title The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.